Skip to main content

Fiscal Wizard · Single-issue tearsheet

NBP / Jun 22, 2026 Run #7644

NBP

NovaBridge Biosciences

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Composite verdict

F 16.7 / 100
Bearish setup · Crossover 6 drivers · 4 gates blocking
  • Engulfing
  • Rate of Change
  • ADX DI Cross
Consider long put target Δ ~0.60 · ~35 DTE Bearish setup, Grade B → ITM put target

Industry rank 323rd of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 19 signals100% Bear
Momentum Bearish 1Mean-reversion Neutral 49
  • Late-stage trendTrend signals have been live for 164 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

33.1 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Return on Assets 77
Free Cash Flow Yield 0
P/B 75
Return on Equity 25
Asset Turnover 25

Technicals Bearish

0.2 / 100

Bearish setup leads (Engulfing, Rate of Change, ADX DI Cross); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 13
Engulfing 14
ADX DI Cross 19

Risk Gates

4 blocking 5 caution

4 guards active, 21 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for NBP.